His6-3C-MAP1LC3a-Dha

His6-3C-MAP1LC3a-Dha

details

His6-3C-MAP1LC3a-Dha is an activity-based probe for E1 activating enzymes and E2 conjugating enzymes that are involved in autophagy (e.g. ATG7 and ATG3, respectively). UbiQ-158 is based on the MAP1LC3a protein sequence in which the C-terminal Gly has been replaced by a dehydroalanine residue (Dha). The N-terminus is labeled with an His6 affinity tag and a 3C protease cleavage site (QG), Cys17 has been mutated to a Ser residue (S). The design of UbiQ-158 allows it to be processed in a native manner by E1-E2-E3 enzymes that recognize MAP1LC3a and during this process it forms an electrophilic intermediate that can react with an active-site Cys residue in the E1-E2-E3 cascade, thereby creating a covalent bond.

Product Attachments

View FileUbiQ-158 productsheet B01092016-001
crystallizationwestern blot

Qty Available: 0

€350.00
€350.00

Request product in bulk

mg
name His6-3C-MAP1LC3a-Dha
product code UbiQ-158
Applications crystallization, western blot
target E1/E2/E3
source human sequence, recombinant protein precursor from E. coli
shipping lyophilized powder
purity ≥95% by RP-HPLC
molecular weight 16.18 kDa
storage Powder at −20°C; solution at −80°C. Protect from light. Please avoid multiple freeze/thaw cycles.
sample preparation For detailed sample preparation see product sheet.
regulatory statement For laboratory research use only, not for use in humans.
    • UbiQ-158 references

      Mulder et al. Nat. Chem. Biol. 2016, 12, 523. 

      https://www.ncbi.nlm.nih.gov/pubmed/27182664

       

      MPC Mulder, F. El Oualid and H. Ovaa. Adenylation enzyme inhibitors. Application WO/2016/032332 and NL2015/050596

    • UbiQ-Probes crystallization overview download this pdf
    • UbiQ's drug discovery expertise overview

       

      download this pdf